Exelon Sees 12% Growth in Data-Center Demand Amid Rising Electricity Consumption
ByAinvest
Tuesday, Nov 4, 2025 12:18 pm ET1min read
AXSM--
Axsome Therapeutics (AXSM) reported a Q3 loss of 94 cents per share, wider than the Zacks Consensus Estimate of a loss of 82 cents. Total revenues surged 63% YoY to $171 million, beating the Zacks Consensus Estimate of $164 million. The year-over-year increase in revenues can be attributed to strong sales of Auvelity. Net product revenues were $169.8 million, reflecting an increase of 63.7% YoY.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet